Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Central tendency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Central tendency. Displaying page 1 of 1.
    EudraCT Number: 2007-004250-81 Sponsor Protocol Number: AKREMITOLFMRI1 Start Date*: 2007-09-11
    Sponsor Name:Helsinki University Central Hospital, Pain Clinic
    Full Title: Acute opioid tolerance as revealed by functional magnetic resonance imaging.
    Medical condition: akuutti opioiditoleranssi
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052804 Drug tolerance LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000219-24 Sponsor Protocol Number: 3082A-101342 Start Date*: 2005-04-28
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A multicentre study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital haemophilia A who develop de novo factor VIII inhibitors while receiving fac...
    Medical condition: Haemophilia A is an X-linked recessive clotting disorder in which the clotting factor, factor VIII (FVIII), is deficient or inactive. Patients with low levels of FVIII have an increased tendency t...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002456-24 Sponsor Protocol Number: 3082B2-4418 Start Date*: 2015-04-10
    Sponsor Name:Wyeth Research
    Full Title: A Post Authorization Safety Surveillance Study of Xyntha in Usual Care Settings
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060612 Hemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000499-32 Sponsor Protocol Number: FSJD-ABELNEB-2010 Start Date*: 2011-09-29
    Sponsor Name:FUNDACIÓ SANT JOAN DE DEU
    Full Title: A PHASE II CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF AMPHOTERICIN B LIPID COMPLEX (ABELCET®) FOR THE PROPHYLAXIS OF INVASIVE PULMONARY ASPERGILLOSIS DURING PROLONGED NEUTROPENIA IN ...
    Medical condition: Invasive pulmonary aspergillosis in patients with acute myeloblastic or lymphoblastic leukaemia.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002378-26 Sponsor Protocol Number: STRIX-MSext001 Start Date*: 2014-11-13
    Sponsor Name:Västerbottens Läns Landsting
    Full Title: Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy app...
    Medical condition: The original trial (EudraCT 2010-023021-38) recruited 74 patients with relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (D...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002105-22 Sponsor Protocol Number: EVL-VHC-HVH.12 Start Date*: 2012-08-17
    Sponsor Name:Dra Itxarone Bilbao. Servicio de cirugía hepatobiliopancreatica y trasplantes. HUVH
    Full Title: Personal monitoring of liver transplant patients infected with Hepatitis C Virus. Pilot study to compare the evolution of Hepatitis C by receiving immunosuppression with tacrolimus in combination w...
    Medical condition: Recurrence of hepatitis C post-liver transplantation in patients with hepatitic C.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10070678 Hepatitis C recurrent LLT
    14.1 10042613 - Surgical and medical procedures 10024716 Liver transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000127-12 Sponsor Protocol Number: TM006 Start Date*: 2022-01-03
    Sponsor Name:Saniona A/S
    Full Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects ...
    Medical condition: Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 00:59:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA